Multidrug-resistant organisms in dialysis patients

Seminars in Dialysis

Volumn 26, Issue 4, 2013, Pages 447-456

  Calfee, David P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; CHRONIC KIDNEY FAILURE; CROSS INFECTION; DISEASE TRANSMISSION; DRUG EFFECT; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMODIALYSIS; HUMAN; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; OUTPATIENT DEPARTMENT; QUALITY CONTROL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT;

AMBULATORY CARE FACILITIES; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HEMODIALYSIS UNITS, HOSPITAL; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL; RENAL DIALYSIS; RISK ASSESSMENT;

EID: 84880703801     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/sdi.12094     Document Type: Article

References (67)

1. US Renal Data System: 2012 Atlas of CKD and ESRD. Minneapolis, MN: US Renal Data System, 2012. http://www.usrds.org/atlas.aspx, accessed January 15, 2013.
2. Pop-Vicas A, Strom J, Stanley K, D'Agata EM: Multidrug-resistant gram-negative bacteria among patients who require chronic hemodialysis. Clin J Am Soc Nephrol 3:752-758, 2008
3. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP: Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29:1099-1106, 2008
4. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y: The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: Mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 26:166-174, 2005
5. Cosgrove SE: The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 42(Suppl 2):S82-89, 2006
6. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA: Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: A meta-analysis. Clin Infect Dis 41:327-333, 2005
7. Reed S, Friedman J, Engemann J, Griffiths RI, Anstrom KJ, Kaye KS, Stryjewski ME, Szczech LA, Reller LB, Corey GR, Schulman KA, Fowler VG: Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 26:175-183, 2005
8. Shurland S, Zhan M, Bradham DD, Roghmann MC: Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 28:273-279, 2007
9. Klevens RM, Edwards JR, Andrus ML, Peterson KD, Dudeck MA, Horan TC, NHSN Participants in Outpatient Dialysis Surveillance: Dialysis Surveillance Report: National Healthcare Safety Network (NHSN)-data summary for 2006. Semin Dial 21:24-28, 2008
10. Rao A, Kallen A, Horan T, Patel P: Microbiologic characteristics of dialysis and bloodstream infections: National Healthcare Safety Network, 2007-2009. 48th Annual Meeting of the Infectious Diseases Society of America. Canada: Vancouver, 2010. Abstract 393.
11. Centers for Disease Control and Prevention: Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients-United States, 2005. MMWR Morb Mortal Wkly Rpt 56:197-199, 2007
12. Kallen A, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, Ray SM, Harrison LH, Lynfield R, Dumyati G, Townes JM, Schaffner W, Patel PR, Fridkin SK: Health care-associated invasive MRSA infections, 2005-2008. JAMA 304:641-648, 2010
13. Fluck R, Wilson J, Tomson C: UK Renal Registry 12th Annual Report (December 2009): Chapter 12: Epidemiology of methicillin resistant Staphylococcus aureus bacteraemia amongst patients receiving dialysis for established renal failure in England in 2008: A joint report from the UK Renal Registry and the Health Protection Agency. Nephron Clin Pract 115(Suppl 1):c261-270, 2010
14. Richter SS, Satola SW, Crispell EK, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Diekema DJ, Doern GV: Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States. J Clin Microbiol 49:4203-4207, 2011
15. Kelley PG, Gao W, Ward PB, Howden BP: Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): Implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 66:1057-1060, 2011
16. Centers for Disease Control and Prevention: Staphylococcus aureus resistant to vancomycin -United States, 2002. MMWR Morb Mortal Wkly Rpt 51:565-567, 2002
17. Sievert D, Rudrik J, Patel J, McDonald LC, Wilkins MJ, Hageman JC: Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 46:668-674, 2008
18. Chung G, Cha J, Han S, Jang H, Lee K, Yoo J, Kim H, Eun S, Kim B, Park O, Lee Y: Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006. J Microbiol Biotechnol 20:637-642, 2010
19. Sánchez García M, De la Torre MA, Morales G, Pelaez B, Tolon MJ, Domingo S, Candel FJ, Andrade R, Arribi A, Garcia N, Martinez Sagasti F, Fereres J, Picazo J: Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 303:2260-2264, 2010
20. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653-665, 2006
21. van Hal SJ, Paterson DL: Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 55:405-410, 2011
22. Patel G, Jenkins SG, Mediavilla JR, Kreiswirth BN, Radbill B, Salgado CD, Calfee DP: Clinical and molecular epidemiology of methicillin-resistant Staphylococcus aureus among patients in an ambulatory hemodialysis center. Infect Control Hosp Epidemiol 32:881-888, 2011
23. Lu P, Tsai J, Chiu Y, Chang FY, Chen YW, Hsiao CF, Siu LK: Methicillin-resistant Staphylococcus aureus carriage, infection and transmission in dialysis patients, healthcare workers and their family members. Nephrol Dial Transplant 23:1659-1665, 2008
24. Salgado C, Farr B: What proportion of hospital patients colonized with methicillin-resistant Staphylococcus aureus are identified by clinical microbiological cultures? Infect Control Hosp Epidemiol 27:116-121, 2006
25. Huang S, Rifas-Shiman S, Warren D, Fraser VJ, Climo MW, Wong ES, Cosgrove SE, Perl TM, Pottinger JM, Herwaldt LA, Jernigan JA, Tokars JL, Diekema DJ, Hinrichsen VL, Yokoe DS, Platt R: Improving methicillin-resistant Staphylococcus aureus surveillance and reporting in intensive care units. J Infect Dis 195:330-338, 2007
26. Eguia J, Liu C, Moore M, Wrone EM, Pont J, Gerberding JL, Chambers HF: Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area. Clin Infect Dis 40:1617-1624, 2005
27. Mermel L, Eells S, Acharya M, Cartony JM, Dacus D, Fadem S, Gay EA, Gordon S, Lonks JR, Perl TM, McDougal LK, McGowan JE, Maxey G, Morse D, Tenover FC: Quantitative analysis and molecular fingerprinting of methicillin-resistant Staphylococcus aureus nasal colonization in different patient populations: A prospective, multicenter study. Infect Control Hosp Epidemiol 31:592-597, 2010
28. Johnson L, Jose J, Yousif F, Pawlak J, Saravolatz LD: Prevalence of colonization with community-associated methicillin-resistant Staphylococcus aureus among end-stage renal disease patients and healthcare workers. Infect Control Hosp Epidemiol 30:4-8, 2009
29. Ghasemian R, Najafi N, Makhlough A, Khademloo M: Frequency of nasal carriage of Staphylococcus aureus and its antimicrobial resistance pattern in patients on hemodialysis. Iran J Kidney Dis 4:218-222, 2010
30. Oumokhtar B, Elazhari M, Timinouni M, Bendahhou K, Bennani B, Mahmoud M, El Ouali Lalami Sanae A, Berrada S, Arrayhani M, Squalli Houssaini T: Staphylococcus aureus nasal carriage in a Moroccan dialysis center and isolates characterization. Hemodial Int doi: 10.1111-j.1542-4758.2012.00759.x, 2012
31. Curtin J, Dalziel C: Beat Those Bugs! Implementing contact precautions in community dialysis units for closer-to-home care. Can J Infect Control 25:9-16, 2010
32. Tokars JI, Gehr T, Jarvis WR, Anderson J, Armistead N, Miller ER, Parrish J, Qaiyumi S, Arduino M, Holt SC, Tenover FC, Westbrook G, Light P: Vancomycin-resistant enterococci colonization in patients at seven hemodialysis centers. Kidney Int 60:1511-1516, 2001
33. D'Agata EM, Green WK, Schulman G, Li H, Tang YW, Schaffner W: Vancomycin-resistant enterococci among chronic hemodialysis patients: A prospective study of acquisition. Clin Infect Dis 32:23-29, 2001
34. Kalocheretis P, Baimakou E, Zerbala S, Papaparaskevas J, Makriniotou I, Tassios PT, Iatrou C, Kouskouni E, Zerva L: Dissemination of vancomycin-resistant enterococci among haemodialysis patients in Athens, Greece. J Antimicrob Chemother 54:1031-1034, 2004
35. Hadley A, Karchmer T, Russell G, McBride DG, Freedman BI: The prevalence of resistant bacterial colonization in chronic hemodialysis patients. Am J Nephrol 27:352-359, 2007
36. Atta MG, Eustace JA, Song X, Perl TM, Scheel PJ: Outpatient vancomycin use and vancomycin-resistant enterococcal colonization in maintenance dialysis patients. Kidney Int 59:718-724, 2001
37. Barbosa D, Lima L, Silbert S, Sader H, Cendoroglo M, Draibe S, Camargo L, Vianna L, Belasco A, Sesso R: Evaluation of the prevalence and risk factors for colonization by vancomycin-resistant Enterococcus among patients on dialysis. Am J Kidney Dis 44:337-343, 2004
38. Alexander EL, Morgan DJ, Kesh S, Weisenberg SA, Zaleskas JM, Kaltsas A, Chevalier JM, Silberzweig J, Barrón Y, Mediavilla JR, Kreiswirth BN, Rhee KY: Prevalence, persistence, and microbiology of Staphylococcus aureus nasal carriage among hemodialysis outpatients at a major New York Hospital. Diagn Microbiol Infect Dis 70:37-44, 2011
39. Mountricha A, Platsouka E, Pappas C, Vourli S, Velonakis E, Hadjiconstantinou V, Vatopoulos A, Paniara O: S. aureus nasal carriage among hemodialysis (HD) patients. Clin Nephrol 65:229-230, 2006
40. Resić H, Corić A, Dedeić-Ljubović A, Hukić M, Avdić E, Kukavica N: Prevalence of MRSA infections in patients on hemodialysis. Med Pregl 60(Suppl 2):97-100, 2007
41. Grabsch EA, Burrell LJ, Padiglione A, O'Keeffe JM, Ballard S, Grayson ML: Risk of environmental and healthcare worker contamination with vancomycin-resistant enterococci during outpatient procedures and hemodialysis. Infect Control Hosp Epidemiol 27:287-293, 2006
42. Johnson L, Venugopal A, Pawlak J, Saravolatz LD: Emergence of community-associated methicillin-resistant Staphylococcus aureus infection among patients with end-stage renal disease. Infect Control Hosp Epidemiol 27:1057-1062, 2006
43. Lin C, Wang J, Lin C, Chen SY, Wang JT, Wu KD, Chang SC: Methicillin-resistant Staphylococcus aureus bacteremia in patients with end-stage renal disease in Taiwan: Distinguishing between community-associated and healthcare-associated strains. Infect Control Hosp Epidemiol 30:89-92, 2009
44. Marchaim D, Lazarovitch Z, Efrati S, Dishy V, Weissgarten J, Boldur I, Zaidenstein R: Serious consequences to the use of cephalosporins as the first line of antimicrobial therapy administered in hemodialysis units. Nephron Clin Pract 101:c58-64, 2005
45. Centers for Disease Control and Prevention: Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 50:1-43, 2001
46. O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S, Healthcare Infection Control Practices Advisory Committee (HICPAC): Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 52:e162-193, 2011
47. Centers for Disease Control and Prevention: Guideline for hand hygiene in health-care settings: Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. MMWR Morb Mortal Wkly Rpt 51:1-48, 2002
48. National Opportunity to Improve Infection Control in ESRD (NOTICE): NOTICE Webinar: Improving Infection Control Practices in Dialysis Facilities. 2012 Available at www.hret.org/quality/projects/resources/improving_infection_control_practices_dialysis_09052012.pdf, accessed December 20, 2012.
49. Lanini S, Puro V, Lauria FN, Fusco FM, Nisii C, Ippolito G: Patient to patient transmission of hepatitis B virus: A systematic review of reports on outbreaks between 1992 and 2007. BMC Med 7:15, 2009
50. Thompson ND, Novak RT, Datta D, Cotter S, Arduino MJ, Patel PR, Williams IT, Bialek SR: Hepatitis C virus transmission in hemodialysis units: Importance of infection control practices and aseptic technique. Infect Control Hosp Epidemiol 30:900-903, 2009
51. Arenas MD, Sánchez-Payá J, Barril G, Garcia-Valdecasas J, Gorriz JL, Soriano A, Antolin A, Lacueva J, Garcia S, Sirvent A, Espinosa M, Angoso M: A multicentric survey of the practice of hand hygiene in haemodialysis units: Factors affecting compliance. Nephrol Dial Transplant 20:1164-1171, 2005
52. Zvonar R, Natarajan S, Edwards C, Roth V: Assessment of vancomycin use in chronic haemodialysis patients: Room for improvement. Nephrol Dial Transplant 23:3690-3695, 2008
53. Siegel J, Rhinehart E, Jackson M, Chiarello L, Healthcare Infection Control Practices Advisory Committee: 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Centers for Disease Control and Prevention, Atlanta, GA. Available at http://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf
54. Osono E, Takahashi M, Kurihara S, Ohwada K, Sakurai Y, Onoda N, Takeuchi M, Yoneshima H, Hayama N, Iino Y, Saji M, Shikita R, Takahashi H, Ohkuni H: Effects of "isolating hemodialysis" on prevention of methicillin-resistant Staphylococcus aureus cross-infection in a hemodialysis unit. Clin Nephrol 54:128-133, 2000
55. Holton DL, Nicolle LE, Diley D, Bernstein K: Efficacy of mupirocin nasal ointment in eradicating Staphylococcus aureus nasal carriage in chronic haemodialysis patients. J Hosp Infect 17:133-137, 1991
56. Boelaert JR, De Baere YA, Geernaert MA, Godard CA, Van Landuyt HW: The use of nasal mupirocin ointment to prevent Staphylococcus aureus bacteraemias in haemodialysis patients: An analysis of cost-effectiveness. J Hosp Infect 19(Suppl B):41-46, 1991
57. Boelaert JR, De Smedt RA, De Baere YA, Godard CA, Matthys E, Schurgers ML, Daneels RF, Gordts BZ, Van Landuyt HW: The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrol Dial Transplant 4:278-281, 1989
58. Boelaert JR, Van Landuyt HW, Godard CA, Daneels RF, Schurgers ML, Matthys EG, De Baere YA, Gheyle DW, Gordts BZ, Herwaldt LA: Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 8:235-239, 1993
59. Watanakunakorn C, Brandt J, Durkin P, Santore S, Bota B, Stahl CJ: The efficacy of mupirocin ointment and chlorhexidine body scrubs in the eradication of nasal carriage of Staphylococcus aureus among patients undergoing long-term hemodialysis. Am J Infect Control 20:138-141, 1992
60. Bommer J, Vergetis W, Andrassy K, Hingst V, Borneff M, Huber W: Elimination of Staphylococcus aureus in hemodialysis patients. ASAIO J 41:127-131, 1995
61. Kluytmans JA, Manders MJ, van Bommel E, Verbrugh H: Elimination of nasal carriage of Staphylococcus aureus in hemodialysis patients. Infect Control Hosp Epidemiol 17:793-797, 1996
62. Teo BW, Low SJ, Ding Y, Koh TH, Hsu LY: High prevalence of mupirocin-resistant staphylococci in a dialysis unit where mupirocin and chlorhexidine are routinely used for prevention of catheter-related infections. J Med Microbiol 60:865-867, 2011
63. Kallen AJ, Jernigan JA, Patel PR: Decolonization to prevent infections with Staphylococcus aureus in patients undergoing hemodialysis: A review of current evidence. Semin Dial 24:533-539, 2011
64. Yahav D, Rozen-Zvi B, Gafter-Gvili A, Leibovici L, Gafter U, Paul M: Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: Systematic review and meta-analysis of randomized, controlled trials. Clin Infect Dis 47:83-93, 2008
65. Landry DL, Braden GL, Gobeille SL, Haessler SD, Vaidya CK, Sweet SJ: Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis. Clin J Am Soc Nephrol 5:1799-1804, 2010
66. Wolley MJ, Taylor SL, Hossain F, Abbas SA, Marshall MR: Association between antimicrobial locks for hemodialysis central venous catheters and antibiotic resistance. Hemodial Int 16(Suppl 1):S2-9, 2012
67. Fernández-Gallego J, Martín M, Gutiérrez E, Cobelo C, Frias P, Jironda C, Hidalgo P, Jimenez T: Prophylaxis with gentamicin locking of chronic tunnelled central venous catheters does not cause bacterial resistance. Nefrologia 31:308-312, 2011